Dr. Neda Hashemi Sadraei
Claim this profileUniversity of New Mexico Cancer Center
Studies Parotid Gland Cancer
Studies Bladder Cancer
14 reported clinical trials
40 drugs studied
Area of expertise
1Parotid Gland Cancer
Stage IV
Stage III
2Bladder Cancer
Stage IV
Stage III
Affiliated Hospitals
Clinical Trials Neda Hashemi Sadraei is currently running
Hormone + Radiation Therapy
for Prostate Cancer
This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving a shorter hormone therapy treatment may work the same at controlling prostate cancer compared to the usual 24 month hormone therapy treatment in patients with low gene risk score. Adding apalutamide to the usual treatment may increase the length of time without prostate cancer spreading as compared to the usual treatment in patients with high gene risk score.
Recruiting2 awards Phase 36 criteria
Relugolix + Radiation
for Advanced-Stage Prostate Cancer
This phase II trial compares the usual treatment of radiation therapy alone to using the study drug, relugolix, plus the usual radiation therapy in patients with castration-sensitive prostate cancer that has spread to limited other parts of the body (oligometastatic). Relugolix is in a class of medications called gonadotropin-releasing hormone (GnRH) receptor antagonists. It works by decreasing the amount of testosterone (a male hormone) produced by the body. It may stop the growth of cancer cells that need testosterone to grow. Radiation therapy uses high-energy x rays or protons to kill tumor cells. The addition of relugolix to the radiation may reduce the chance of oligometastatic prostate cancer spreading further.
Recruiting0 awards Phase 2
More about Neda Hashemi Sadraei
Clinical Trial Related5 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Neda Hashemi Sadraei has experience with
- Nivolumab
- Pembrolizumab
- Radiation Therapy
- Avelumab
- Durvalumab
- Ipilimumab
Breakdown of trials Neda Hashemi Sadraei has run
Parotid Gland Cancer
Bladder Cancer
Prostate Adenocarcinoma
Cancer
Cystic Tumor
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Neda Hashemi Sadraei specialize in?
Is Neda Hashemi Sadraei currently recruiting for clinical trials?
Are there any treatments that Neda Hashemi Sadraei has studied deeply?
What is the best way to schedule an appointment with Neda Hashemi Sadraei?
What is the office address of Neda Hashemi Sadraei?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.